Kalaris Therapeutics (NASDAQ:KLRS) Rating Lowered to Sell at Wall Street Zen

Kalaris Therapeutics (NASDAQ:KLRS) was downgraded by equities researchers at Wall Street Zen from a “hold” rating to a “sell” rating in a research note issued to investors on Saturday.

Other analysts have also recently issued reports about the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Kalaris Therapeutics in a research note on Monday, December 29th. Citigroup restated an “outperform” rating on shares of Kalaris Therapeutics in a research note on Thursday, December 18th. Finally, Chardan Capital assumed coverage on shares of Kalaris Therapeutics in a report on Tuesday, December 23rd. They issued a “buy” rating and a $19.00 target price for the company. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $14.00.

Kalaris Therapeutics Trading Up 1.4%

NASDAQ KLRS opened at $9.82 on Friday. Kalaris Therapeutics has a 12 month low of $2.14 and a 12 month high of $12.90. The stock has a market cap of $183.63 million, a price-to-earnings ratio of -2.60 and a beta of -0.13. The company’s 50 day moving average is $9.36 and its two-hundred day moving average is $6.91.

Insider Buying and Selling at Kalaris Therapeutics

In other Kalaris Therapeutics news, Director Srinivas Akkaraju bought 479,847 shares of the firm’s stock in a transaction dated Thursday, December 18th. The stock was acquired at an average cost of $10.42 per share, for a total transaction of $5,000,005.74. Following the completion of the transaction, the director owned 1,979,847 shares in the company, valued at $20,630,005.74. This trade represents a 31.99% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Company insiders own 74.99% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in the stock. Bridgeway Capital Management LLC bought a new stake in shares of Kalaris Therapeutics during the third quarter valued at approximately $130,000. Walleye Capital LLC bought a new position in Kalaris Therapeutics in the fourth quarter worth approximately $95,000. XTX Topco Ltd purchased a new position in Kalaris Therapeutics during the 4th quarter worth $92,000. Keel Point LLC purchased a new position in Kalaris Therapeutics during the 4th quarter worth $86,000. Finally, Johnson Financial Group Inc. bought a new stake in Kalaris Therapeutics during the 3rd quarter valued at $58,000. Hedge funds and other institutional investors own 66.05% of the company’s stock.

About Kalaris Therapeutics

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.